Phosphatase and tensin homolog deleted on chromosome 10 (PTEN)

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a multifunctional enzyme encoded by the PTEN gene on human chromosome 10q23. It possesses both lipid and protein phosphatase activities, predominantly dephosphorylating the phosphoinositide PI(3,4,5)P₃, thereby antagonizing the phosphoinositide 3-kinase (PI3K)/AKT axis, a critical cell survival and proliferation signaling pathway[1][2][3][4][5][6]. PTEN inhibits cell cycle progression, induces apoptosis, and maintains genomic stability. It plays essential roles during embryogenesis and in adult tissues, with subcellular localization (cytoplasmic and nuclear) modulating its functions. Germline or somatic mutations in PTEN are strongly implicated in a variety of cancers and genetic syndromes, where loss or inactivation of PTEN leads to unchecked cell growth, migration, and survival[1][2][3][4][5][6][7]. There are no approved drugs that directly target PTEN, but assessing PTEN status is crucial for therapeutic decision-making, especially when using agents targeting the PI3K/AKT/mTOR pathway[6][7]. PTEN’s complex regulatory mechanisms, including various post-translational modifications, subcellular compartmentalization, and protein-protein interactions, present both challenges and opportunities for therapeutic exploitation[4][5][6].

Other names

PTENMutated in multiple advanced cancer 1 (MMAC1)TEP1PTEN/MMAC1/TEP1

Restoration/enhancement of PTEN activity or mimicry: reduces PI3K/AKT/mTOR signaling, inhibits cell proliferation and promotes apoptosis Indirect inhibition of downstream pathways (PI3K, AKT, mTOR) in PTEN-deficient tumors